Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
QHSLab ( (USAQ) ) has provided an announcement.
On March 31, 2026, QHSLab reported its fiscal 2025 results, highlighting that revenue rose 26% year over year to about $2.69 million and gross margin widened to 67.3%. The company posted net income of $457,417 versus a loss in 2024, while cash climbed to $636,157 and current liabilities fell sharply to roughly $450,000 following debt repurchases, restructuring, and the extinguishment of most funded and convertible debt.
Operationally in 2025, growth was driven by QHSLab’s Integrated Service Program, where revenue jumped 74% to about $1.12 million, alongside a roughly 19% increase in immunotherapy sales that diversified revenue across diagnostics, therapeutics, and digital health services. Management emphasized that improved profitability, margin expansion, and a strengthened balance sheet position the digital health firm to pursue further growth in its primary care-focused population health and care management offerings in 2026.
The most recent analyst rating on (USAQ) stock is a Buy with a $0.64 price target. To see the full list of analyst forecasts on QHSLab stock, see the USAQ Stock Forecast page.
Spark’s Take on USAQ Stock
According to Spark, TipRanks’ AI Analyst, USAQ is a Neutral.
The score is driven primarily by improved 2025 financial performance (profitability turnaround, deleveraged balance sheet, and positive cash flow) and supportive corporate events around debt reduction and governance. This is tempered by weak technical momentum (bearish trend signals) and only moderate valuation support (P/E ~16, no dividend yield provided).
To see Spark’s full report on USAQ stock, click here.
More about QHSLab
QHSLab, Inc. is a digital health infrastructure company that supports independent primary care practices with workflow-integrated digital screening, clinical decision support, and care management services. The company generates primarily recurring revenue from medical practices and also operates an allergy diagnostics and allergen immunotherapy business under the AllergiEnd brand, targeting underdiagnosed behavioral and chronic conditions.
The firm’s platform enables physicians to conduct reimbursable clinical activities both during and outside traditional office visits, focusing on areas such as anxiety, depression, chronic pain, allergy, and sleep disorders. Its integrated service offerings and mix of diagnostics, therapeutics, and digital tools aim to help primary care providers expand population health screening and care management programs.
Average Trading Volume: 9,780
Technical Sentiment Signal: Buy
Current Market Cap: $6.43M
For a thorough assessment of USAQ stock, go to TipRanks’ Stock Analysis page.